ReviewJournal of thoracic disease2018
Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy.
Review in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact.Therapeutic advances in medical oncology · 2025Article
- FOXA1/CK7-positive Esophageal Squamous Cell Carcinoma with Aggressive Liver Metastasis.Internal medicine (Tokyo, Japan) · 2024Article
- Rapid tumor progression complicated with liver abscess in a patient with gastric cancer receiving nivolumab therapy.International cancer conference journal · 2024Article
- Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90.Clinical lung cancer · 2023Article
- Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives.Molecular biology reports · 2023Review
- Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer.Frontiers in immunology · 2023Review
- Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC).Biomedicines · 2022Article
- Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.Cancer immunology, immunotherapy : CII · 2022Article
- Article
- Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors.The British journal of radiology · 2021Review
- Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions.Cancers · 2021Review
- Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.Translational lung cancer research · 2021Review
- Article
- Preclinical Pharmacokinetics and Dosimetry of anFrontiers in medicine · 2021Article
- Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab.Oncology letters · 2021Article
- Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.Journal of cancer research and clinical oncology · 2020Article
- Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors.Immune network · 2020Article
- Review
- Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.Cancers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy agents in metastatic non-small cell lung cancer (NSCLC) can result in improved quality of life and survival when compared with platinum-based chemotherapy. Novel response patterns such as pseudoprogression and hyperprogression, however, have been described and pose a challenge to treating physicians. Predictors of hyperprogressive disease (HPD) have not yet been identified. Evaluation and management by a multidisciplinary team involving medical and radiation oncologists, thoracic radiologists, and proceduralists is necessary to identify this subset of patients in a timely manner. Repeat biopsy distinguishes HPD from pseudoprogression and may eventually elucidate predictive biomarkers. We describe the epidemiology of these two phenomena, their diagnostic criteria, and their relevance for interventional pulmonologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.